BHB-1893 versus metoprolol for hypertrophic cardiomyopathy symptoms
Treatments studied
Part of Heart & circulation clinical trials.
This study tests a new medicine, BHB-1893, against a common heart medicine called metoprolol for people with a heart condition that makes it harder for the heart to pump blood. The goal is to see if BHB-1893 improves symptoms like chest pain and shortness of breath better than the standard medicine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with obstructive hypertrophic cardiomyopathy (oHCM), a condition where the heart muscle is thickened and blocks blood flow.
- Your symptoms are significant enough to limit some daily activities (classified as class II or III by your doctor).
- You need to be able to have a clear ultrasound of your heart, so the doctors can see how it is working.
- You should not be taking beta-blockers or calcium-channel blockers for any other heart condition, and you must be willing to stop those if needed.
- You must not have a history of bad reactions to beta-blocker medicines.
- Your resting blood pressure should be below 160 mmHg and your resting heart rate below 100 beats per minute.
- You should not have other significant heart valve problems that are not caused by your hypertrophic cardiomyopathy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether two common heart medicines, bisoprolol and verapamil, improve symptoms in adults with non-obstructive hypertrophic cardiomyopathy. It may help you and your care team understand which medicine works better for symptom control and heart function.
This trial tests a new drug, Aom0304, for people with hypertrophic cardiomyopathy (a condition where the heart muscle is thickened) who still have symptoms despite standard treatments. The study aims to see if the drug can improve symptoms and heart function.
This study tests the long-term safety of the drug HRS-1893 in people with hypertrophic cardiomyopathy who have already been in a previous HRS-1893 study. It helps doctors learn more about how safe the drug is over time.
This study looks at how heart medications affect blood flow in people with obstructive hypertrophic cardiomyopathy. You will have a heart MRI before and after starting or adjusting treatment to see how your heart responds.
This trial tests a medication called Ademetionine for people with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle is thick and blocks blood flow). It aims to see if the drug can help improve symptoms and exercise ability.
This trial uses a special CT scan to create a 3D model of your heart's blood flow. It aims to see if this model can help doctors better predict how well treatments work for people with a thick heart muscle that blocks blood flow.
Hear when a new Cardiomyopathy, Hypertrophic Obstructive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.